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Abstract
Background: Irritable bowel syndrome (IBS) and gastrointestinal (GI) dysmotility disorders have a similar clinical
picture, although dysmotility disorders require the attention of a specialist. Patients with primary Sjögren’s
syndrome (pSS) have also been described to suffer from IBS-like symptoms. No objective marker is available to
distinguish between the patients. A visual analogue scale has been developed for IBS patients (VAS-IBS) to measure
treatment response of GI symptoms and well-being in patients with IBS. The aim of the present study was to
examine if VAS-IBS could be used to compare the degree of GI complaints in different patient populations, to get
an objective marker to differentiate between the patients.
Methods: The VAS-IBS consists of 7 VAS scales, namely, abdominal pain, diarrhoea, constipation, bloating and
flatulence, vomiting and nausea, psychological well-being and the intestinal symptoms’ influence on daily life.
Consecutive female patients suffering from IBS, dysmotility disorders and pSS were asked to complete the VAS-IBS
questionnaire when visiting the out-patient clinics. In addition, a control population consisting of healthy female
volunteers was included.
Results: Healthy volunteers had almost no GI symptoms, whereas all 3 patient groups expressed symptoms. There
was no statistical significant difference between IBS and dysmotility in any of the scales besides vomiting and
nausea (p = 0.044). Except for constipation, patients with pSS had less severe symptoms than the others.
Conclusion: The VAS-IBS questionnaire could be used to assess the level of GI symptoms. However, VAS scores do
not help the clinicians to differentiate between IBS and other dysmotility disturbances.
Background
Irritable bowel syndrome (IBS) is a common, functional,
gastrointestinal (GI) disorder, affecting a significant
number of people, predominantly women [1]. Its aetiol-
ogy and pathophysiology is insufficiently understood.
Abdominal pain and bloating are the dominant and
most troublesome symptoms of IBS [1]. It is difficult in
clinical practice to estimate the symptomatic changes
occurring in patients with IBS based on their descrip-
tion. It is equally difficult in description and to evaluate
the effect of different treatments. Hence, there is a need
to translate the patients’ perception of their symptoms
and their subjective well-being into quantitative para-
meters. Several disease-specific questionnaires have been
developed during the last years to try to evaluate GI
symptoms in an objective manner. However, most of
these are too time-consuming to be used in daily clinical
practice. The visual analogue scale for IBS (VAS-IBS)
has therefore been developed and validated, offering a
short and patient-reported questionnaire to be used in
clinical practice for these patients [2]. The original pur-
pose to develop this questionnaire was to measure treat-
ment response of GI symptoms and well-being in
patients with IBS.
Primary Sjögren’s syndrome (pSS) is an autoimmune
disease mainly affecting exocrine glands, leading to
decreased secretion and mucosal dryness. Recently, we
have described that a great number of these patients
also suffer from functional bowel symptoms [3,4].
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obstruction (CIPO) are GI diseases presenting with the
same type of symptoms as functional bowel diseases,
but with objective signs of dysmotility disturbances and/
or histopathological changes in the bowel wall [5,6].
Clinically, it may be difficult to differentiate between
severe IBS and dysmotility disorders at the initial meet-
ing. The latter are patients who need more advanced
health care than IBS patients and should be cared for by
specialists in gastroenterology [7,8]. Sometimes patients
with dysmotility disorders are not correctly diagnosed
for many years [7]. No objective markers are easily avail-
able to differentiate between the entities at first contact.
Besides sharing the same type of symptoms with unclear
aetiology, patients with both IBS, CIPO, ED and pSS
have in common expression of high serum titres of anti-
bodies against gonadotropin-releasing hormone (GnRH)
[3,9-11]. The hypothesis was that the VAS-IBS scale
could be an objective marker to distinguish between
these patient populations, thereby helping the clinicians
to tailor a correct examination and treatment.
The aim of the present study was thus to compare the
degree of GI complaints in different patient populations
known for their presence of functional bowel symptoms
and high prevalences of GnRH antibodies, to get objec-
tive markers for differentiation between patients at an
early stage, and to see if any group of patients with
symptoms of dysmotility could be simply identified
using the VAS-IBS scale.
Methods
This study was performed according to the Helsinki
declaration and was approved by the Ethics Committee
of Lund University. Patients were consecutive patients at
Skåne University Hospital, Malmö. All patients and con-
trols gave informed consent before entering the study.
As symptoms of functional bowel disorders may differ
between men and women, and the vast majority of these
patients are women, only women were studied.
Subjects
Controls
The control group was recruited among hospital staff
and consisted of 52 healthy female volunteers (median
age 44 years, range 22 - 77 years) who had not under-
gone prior abdominal surgery.
Patients with irritable bowel syndrome (IBS)
All consecutive female patients visiting the out-patient
clinic at the Department of Gastroenterology, during a
2-year period, suffering from abdominal pain and symp-
toms of altered bowel habits were investigated according
to standard norms depending on the severity of symp-
toms. Investigation comprising radiological and/or endo-
scopic examination to rule out organic disease was
performed when clinically indicated. Appropriate labora-
tory samples were analyzed. Patients with GI symptoms
but without abnormal findings on the examinations
mentioned above, who fulfilled the Rome-III criteria,
were classified as IBS [1]. These 39 patients (median age
37 years, range 18-69 years) were thus invited to partici-
pate in this study. None of the patients declined to par-
ticipate. All patients were working full time, and were
not dependent on nutritional support or opioid analge-
sics. However, their psychological state was not exam-
ined. They were all referred back to the primary health
care center from which they came for continued care
after examination at the University Hospital.
Patients with dysmotility disorders
Consecutive female patients subjected to laparoscopic
full-thickness biopsy at the Department of Surgery or
Gastroenterology, during a 10-year period, because of
severe GI pain and dysmotility were included. In addi-
tion, patients with symptoms of severe dysmotility who
underwent intestinal resection within the same time
frame were included, but were not considered for
laparoscopic biopsy because full-thickness bowel wall
tissue was already available for histochemical examina-
tion and thereby histopathological classification [9,10].
They all underwent extensive examinations with oeso-
phagogastroduodenoscopy, enterography or capsule
endoscopy, ileocolonoscopy and abdominal ultrasound
depending on the symptoms present. In some cases this
had already been performed repeatedly for several years.
Routine analyses were performed on blood and urinary
samples. The GI examination was then further com-
pleted with oesophageal manometry, gastric emptying
scintigraphy, antroduodenojejunal manometry, colonic
transit time and full-thickness biopsies of the distal
ileum, depending on the clinical picture [5,6,9,10,12-14].
Patients who fulfilled the 3 criteria: a medical history
compatible with pseudo-obstruction, documented events
or chronic signs mimicking mechanical obstruction
(bowel dilatation and/or air/fluid levels) and absence of
mechanical obstruction or other organic cause for these
symptoms and findings were classified as CIPO [6]. The
criteria for ED were gastrointestinal symptoms that were
severe enough to warrant referral for small bowel mano-
metry, presence of abnormal contractile activity, but
absence of sub-occlusion episodes and absence of any
medication that could lead to observed motor abnormal-
ities [5]. These patients represent the vast majority of
cases of suspected CIPO/ED in the southern part of
Sweden, as the listed departments constitute the tertiary
referral centre for GI dysmotility in this region.
Thirty-one female patients were recognised in a retro-
spective manner. Twenty-one patients (median age 43
years, range 26-84 years) accepted to participate in the
study. Out of these, 16 had ED and 5 had CIPO. As a
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difference in symptoms between these 2 groups, they
were regarded as one group in the statistical calculations
[7,8]. Ten of the patients had peroral nutrition, whereas
11 had supplements of enteral or intravenous nutrition.
Seventeen of the patients used opioid analgesics. Only 4
o ft h ep a t i e n t sw o r k e df u l lt i m e ,a n d2a n d1w o r k e d
75% and 50% of full time, respectively. Ten were retired
because of disease and 1 because of age.
Patients with primary Sjögren’s syndrome (pSS)
Thirty-five consecutive female patients with pSS at the
Department of Rheumatology, according to the American-
European Consensus Criteria (AECC) [15], who had pre-
viously been included in a study on autonomic dysfunction
(AD) [16], were asked to participate in this study. Twenty-
six pSS patients (median age 62 years, range 29-65 years)
were willing to be included in the study. None of the
patients had previously undergone GI surgery.
Questionnaire
Self estimation on gastrointestinal symptoms - VAS-IBS
questionnaire
Patients estimated 7 different entities on a VAS scale
from 0 - 100 mm where 0 represents very severe pro-
blems and 100 represents absence of problems. The 7
entities were abdominal pain, diarrhoea, constipation,
bloating and flatulence, vomiting and nausea, perception
of mental well-being and the intestinal symptoms’ effect
on daily life. This questionnaire has formerly been
developed and psychometrically tested for patients with
GI symptoms without organic reasons [2].
The questionnaire was sent by mail to all participants
with dysmotility disorders and all controls, and returned
to the investigator in an envelope, after completion.
Patients with IBS and pSS completed the questionnaire
at the visit at the departments.
Statistical analyses
Values are given as median, interquartile range (IQR). As
the pSS patient group was significantly older than the other
groups, variables were age-standardized using a linear
regression model into which age was added as a covariate
and the variables were expressed as z-scores. When com-
paring VAS scores between groups, the age-standardized
values were used. Differences between groups were calcu-
lated by Kruskal-Wallis test. There were statistically signifi-
cant differences between groups, why the calculations were
followed by Mann Whitney U test, which are the values
shown. P < 0.05 was considered statistically significant.
Results
Controls
The control group did not differ in age compared to
patients with IBS and dysmotility (data not shown), but
were younger than the pSS patients (p = 0.000). Age did
not significantly influence the variables in the VAS-IBS
(data not shown). Healthy subjects scored high values
on the VAS scale (median values 95-100, interquartile
ranges 78-100), except for bloating and flatulence that
was present also in controls (86 (71-99)).
Irritable bowel syndrome (IBS) and dysmotility disorders
Both patients with IBS and dysmotility disorders rated
their GI symptoms as more severe compared to con-
trols. Both groups differed significantly from controls in
all variables. There was no statistical difference in any of
the individual symptoms between these two groups,
except for vomiting and nausea (Table 1). Influence of
GI symptoms on daily life was rated as the worst symp-
tom, followed by bloating and flatulence. Although they
reported great impact on daily life, their overall psycho-
logical well-being was not affected to the same extent
(Table 1).
Primary Sjögren’s syndrome (pSS)
All variables differed significantly between controls and
patients with pSS (Table 1). Patients with pSS rated
their GI symptoms as less severe than patients with IBS
and dysmotility. They had significantly less severe symp-
toms than IBS patients in all variables except for consti-
pation (p = 0.186). Compared to patients with
dysmotility disorders, they differed in all variables except
constipation (p = 0.247) and psychological well-being (p
= 0.252) (Table 1).
Discussion
In this study, we estimated GI symptoms in 3 different
patient cohorts with known GI complaints without
gross organic changes in the bowel wall. The results
showed that patients with pSS had less severe GI com-
p l a i n t st h a np a t i e n t sw i t hp r i m a r yG Id i a g n o s i ss u c ha s
IBS and dysmotility disorders, which did not differ in
symptoms except for vomiting and nausea.
Surprisingly, there was not any difference in any para-
meter measured in our study between patients with IBS
and dysmotility disorders except for vomiting and nau-
sea. Patients with dysmotility disorders have pathological
examinations when examining GI motility and histo-
pathological changes in full-thickness biopsies [5,6].
They are often dependent on nutritional support to
keep weight and avoid malnutrition, are dependent of
analgesics and are not able to work [7]. On the contrary,
patients with IBS have no objective changes pathog-
nomic for the disease. Instead, the diagnosis is set when
patients fulfil the Rome III criteria, based on presence of
various GI symptoms [1]. Most IBS patients maintain
normal weight and are able to eat without nutritional
support, work full-time and never use opioid analgesics
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to have a severe chronic GI disease which needs
advanced care by specialists [7,8], whereas patients with
IBS according to recommendations should be managed
in the primary health care system, or by themselves
[17]. Still, IBS patients, in the present study, score their
GI symptoms as severe as patients with dysmotility dis-
orders do.
Our results are in contrast to another study showing
that IBS patients have less severe GI symptoms and bet-
ter quality of life than CIPO patients [18]. It has been
shown that significant impairments of health-related
quality of life can only be detected in IBS patients with
severe symptoms [19]. Female IBS patients have more
severe GI symptoms and a reduced quality of life com-
pared to male patients, and female patients at a hospital
have reduced quality of life compared to patients at a
primary care centre [20]. Hence, our patients constitute
a highly selected group. Some explanations to the differ-
ent results in our study compared to Cogliandro et al.
[18] may depend on our smaller sample size, and that
patients of both genders were included in the latter
study, whereas only women were included in the present
study. Both studies were performed at a tertiary GI cen-
tre, why selected IBS patients with severe symptoms
were included. Thus, our results may not be applied to
the general IBS population in the community, but may
reflect the IBS patients often seen at a specialist centre.
If this study on IBS patients had been performed at a
primary health care centre, there had maybe been a dif-
ference in the VAS scales compared to patients with
dysmotility disorders. Further, our patients estimated
their symptoms on a continuous VAS scale, whereas the
patients in the study by Cogliandro et al. [18] scored
their symptoms 0-4, which could also affect the results.
Patients with IBS may have varying degrees of the dis-
ease. Those who seek care are considered sicker than
those who do not, with a higher proportion of abnormal
personality patterns, greater illness behaviour and lower
life events scores than non-patients with IBS [1].
Patients with IBS are associated with an enhanced per-
ception of personal vulnerability to illness and over-
reporting of symptoms [21,22]. This may be due to the
fact that a high percentage of IBS patients suffer from
somatization disorders [23], which in turn may lead to
over-reporting of GI symptoms, wide-spread pain,
migraine, psychiatric symptoms, as well as in an increase
of physicians consulted, medication changes, poor treat-
ment outcomes and treatment dissatisfaction compared
to their counterparts without somatization disorders
Table 1 Comparison between the groups - evaluation of their symptoms being estimated with visual analogue scale
for irritable bowel syndrome (VAS-IBS).
VAS-IBS score Controls = 52 IBS = 39 Dysmotility = 21 pSS = 26 Statistically significant p values
Abdominal pain
Z-score 0.22 (-0.41-0.60) -3.43 (-4.23–2.77) -3.34 (-4.42–2.31)27 (12-44) *** -1.08 (-2.31-0.04) IBS vs pSS p = 0.000
Absolute score 95 (85-99) 23 (10-37) *** 73 (54-97) *** pSS vs Dysm p = 0.000
Diarrhoea
Z-score 0.27 (-0.11-0.55) -3.91 (-5.23–0.53) -3.23 (-4.11 - -0.55) -0.75 (-1.97-0.15) IBS vs pSS p = 0.012
Absolute score 97 (90-100) 35 (19-83) *** 49 (33-69) *** 82 (66-98) *** pSS vs Dysm p = 0.049
Constipation
Z-score 0.32 (-0.39-0.76) -0.69 (-2.99-0.54) -1.57 (-3.32-0.60) 0.03 (-2.41-0.63)
Absolute score 91 (78-99) 72 (30-95) ** 54 (18-95) * 86 (42-97) *
Bloating, flatulence
Z-score 0.28 (-0.26-0.77) -2.33 (-2.84–1.06) -2.15 (-2.67 - -1.28) -0.62 (-1.61-0.31) IBS vs pSS p = 0.000
Absolute score 86 (71-99) 17 (3-50) *** 18 (7-45) *** 63 (37-87) *** pSS vs Dysm p = 0.002
Vomiting, nausea
Z-score 0.27 (0.08-0.35) -3.34 (-4.55–0.03) -4.82 (-4.81 - -0.78) 0.08 (-3.14-0.20) IBS vs pSS p = 0.004 IBS vs Dysm
p = 0.044
Absolute score 98 (97-100) 50 (34-94) *** 32 (12-84) *** 97 (54-99) *** pSS vs Dysm p = 0.001
Psychological well-being
Z-score 0.51 (-0.09-0.70) -2.08 (-3.29 - -0.56) -1.79 (-1.79-0.46) -0.76 (-2.29-0.62) IBS vs pSS p = 0.018
Absolute score 96 (84-100) 45 (23-74) *** 51 (22-94) ** 72 (44-98) ***
Influence on daily life
Z-score 0.53 (-0.12-0.59) -3.05 (-3.43 - -2.49) -3.06 (-3.06 - -2.62) 0.20 (-1.75-0.49) IBS vs pSS p = 0.000
Absolute score 98 (82-100) 11 (3-25) *** 8 (3-22) *** 88 (42-96) *** pSS vs Dysm p = 0.000
All p values are calculated using the z-scores. Mann Whitney U test. Patients vs controls; * < 0.05, ** < 0.01, *** < 0.001. IBS = Irritable bowel syndrome, pSS =
primary Sjögren’s syndrome.
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fer from anxiety and/or depression in several studies
[25,26]. Depression and anxiety scores were significantly
correlated with VAS ratings of perceived pain and over-
all discomfort [27]. When examining the neuronal
responses in the brain by functional magnetic resonance
imaging (fMRI), there were significant differences in the
neural processing of pain between IBS patients and con-
trols, supporting the role of affective disturbances in the
neural processing of visceral pain in IBS, and further
underlining the importance of psychological factors in
the pathophysiology of visceral hyperalgesia in these
patients [28,29]. The results in the present study which
showed that the IBS patients experienced their GI symp-
toms as severe as patients with dysmotility disorders,
might be explained by psychological mechanisms
[30,31], as dysmotility patients suffering from severe dis-
ease making them unable to eat and work, still scores at
levels comparable to those of patients with IBS.
The classical symptoms in patients with pSS are dry
eyes and mouth. Recently, we have described that a
great number of these patients also suffer from func-
tional bowel symptoms, dysphagia and impaired gastric
emptying rate [3,4,32]. Thus, pSS is a disease affecting
more than the exocrine glands. It is difficult to say if
pSS patients suffer from true functional bowel disorders,
or if their symptoms are IBS-like symptoms associated
with mucosal inflammation as in the case of inflamma-
tory bowel disease [33], or both. Examinations have
shown oesophageal dysmotility and impaired gastric
emptying rate in these patients [4,32], whereas the rest
of the GI tract has been poorly investigated. They may
suffer from dysmotility also in the small and large intes-
tines, explaining their symptoms. On the other hand,
signs of gastro paresis were found to be poorly corre-
lated with symptoms of IBS [4]. However, they fulfilled
the symptom criteria for IBS and FD in 46% and 89% of
cases [3], respectively, and their prevalence of IBS-like
symptoms are thus higher than in the general popula-
tion which is around 10-15% [34,35].
Besides psychological mechanisms, there is growing
evidence for involvement of immunological mechanisms
in the aetiology of IBS. An increased number of mast
cells have been described in the mucosa of patients with
IBS [36]. Others have described an increased number of
T cells and macrophages [37,38], as well as a correlation
between symptom severity and levels of pro-inflamma-
tory cytokines TNFa and IL-1b suggestive of a direct
effect of cytokines on visceral sensation [39]. Recently,
antibodies against GnRH in serum has been described
in patients suffering from functional and dysmotility dis-
orders, but not in patients suffering from coelic disease
and inflammatory bowel diseases [3,9-11]. Irritable
bowel syndrome thus seems to be a heterogenous
disorder involving both peripheral immunological, psy-
chological and central mechanisms. Immunological
mechanisms seem to be more dominant in post-infec-
tious IBS, and may be a separate entity of the disease
[37-39]. However, also in these patients an over-report-
ing of symptoms and perception of illness seems to be
important [22,23], to explain our results in the present
study.
The present results underline the conflict seen in the
daily practice. Physicians consider changes that can be
objectified as more severe, and treat these patients at
specialist departments, whereas patients with func-
tional diagnosis without objective, measurable changes
are considered less sick and are treated at primary
health care centres. The results of the present study
show that the symptoms are as troublesome for the
patients, independent of presence of objective changes.
The patients need confirmation of their symptoms,
and education to handle their symptoms, as shown
previously [40].
There are several limitations in this study. First, one
limitation of this study is that we have examined
patients during treatment. If we had examined patients
with dysmotility disorders without nutritional support
and analgesics, they had maybe scored worse than the
IBS patients. On the other hand, also the IBS patients
had some sort of palliative treatment. Secondly, the rela-
tively small patient groups as well as the lack of a popu-
lation-based control group are a limitation. Finally, the
selection of female patients at a tertiary GI centre is also
a limitation, making the results hard to apply on the
general IBS population in the community.
Conclusions
Previous studies have shown that the VAS-IBS question-
naire could be used to estimate GI symptoms, and the
degree of symptoms to aid in treatment choice, and
evaluating possible treatment effects. The present study
showed that female IBS patients with functional com-
plaints at a tertiary GI centre experience their symptoms
as severe as patients with dysmotility disorders expres-
sing objective, measurable changes on GI examinations.
VAS scores do not help the clinician at a tertiary GI
centre to differentiate between IBS and more severe dys-
motility disturbances. As our patients comprise a
selected group, our results may not be applied to the
general IBS population in the community.
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